Obesity, Food Assistance, and the Future of Health Policy in Delaware

As more than a dozen states move to restrict certain Supplemental Nutrition Assistance Program (SNAP) purchases beginning in 2026, Delaware has chosen a different path. While other states have received or requested waivers from the U.S. Department of Agriculture (USDA) to limit the use of SNAP benefits for items such as soda and other sugar-sweetened beverages, Delaware has opted not to pursue such restrictions.

This decision arrives at a critical moment for public health. Medical research has long shown that overweight and obesity increase the risk of serious conditions such as Type 2 diabetes, high blood pressure, heart disease and stroke, according to clinical guidance from the National Institute of Diabetes and Digestive and Kidney Diseases. When public nutrition assistance programs allow benefits to be used for products strongly associated with weight gain, it raises an important question: should nutrition assistance and health policy be better aligned to reduce preventable disease and long-term health care costs?

The Health Impact in Delaware

Obesity is not an abstract policy issue in Delaware—it is a measurable and growing health challenge. In 2022, nearly 38% of Delaware adults reported being obese, according to data from the Delaware Department of Health and Social Services (DHSS). The same data show a stark connection between obesity and chronic disease: 23.9% of adults who reported obesity also reported having diabetes, compared with just 5.3% of adults at normal weight.

These trends begin early in life. A 2021 DHSS survey found that about 15% of Delaware high school students reported being obese, and nearly one in three students were overweight or obese. The survey also revealed widespread consumption of sugar-sweetened beverages, low fruit and vegetable intake, and insufficient physical activity among adolescents.

Taken together, these findings suggest that diet-related health risks are established well before adulthood. The consequences—chronic disease, reduced quality of life, and rising health care costs—follow individuals and public programs for decades.

Obesity Treatment and the Rise of GLP-1 Medications

While obesity remains a complex condition influenced by diet, behavior, environment, and genetics, medical treatment options have evolved significantly. One of the most prominent developments is the use of glucagon-like peptide-1 (GLP-1) receptor agonists, including medications such as semaglutide.

These medications are prescribed for obesity and Type 2 diabetes and work by regulating appetite and improving glucose metabolism. Large randomized clinical trials published in The New England Journal of Medicine have shown that GLP-1 medications can lead to sustained weight loss and meaningful improvements in metabolic health.

In Delaware, the use of GLP-1 medications has increased sharply in recent years, according to a 2025 report from the Delaware Department of Insurance. Medicaid in Delaware already covers these medications under defined clinical criteria, recognizing obesity as a treatable medical condition rather than a personal failing.

However, increased use comes with financial implications. The state reports that GLP-1 drugs now account for more than 6% of total pharmacy spending in the fully insured market, highlighting the need to balance access to effective treatment with long-term affordability.

A Disconnect Between Nutrition and Health Policy

Many Delaware residents who receive SNAP benefits are also enrolled in Medicaid. Despite serving overlapping populations, the two programs operate independently. SNAP influences food purchasing decisions and dietary patterns, while Medicaid bears much of the financial burden of treating obesity-related illnesses after they develop.

Under current policy, SNAP benefits can still be used to purchase sugar-sweetened beverages—products state health surveys identify as widely consumed, particularly among young people. These purchasing patterns matter. Public benefits shape behavior, and over time, they influence population-level health outcomes.

From a policy perspective, this separation represents a missed opportunity. Nutrition assistance continues to permit purchases that contribute to obesity, while Medicaid invests heavily in treating the medical consequences of that same condition. Aligning these systems would not require new taxes, expanded eligibility, or mandated treatments. Instead, it would offer individuals the option to use existing public benefits in ways that better support long-term health.

A Path Forward for Delaware

No state has yet formally attempted to align SNAP and Medicaid to address obesity in a coordinated way. That does not mean the idea lacks merit—it means the question has not been tested.

Delaware is uniquely positioned to explore this approach. Its relatively small size, integrated health care infrastructure, and strong data systems make it well suited to serve as a pilot or demonstration state. A coordinated model could evaluate whether closer alignment between nutrition assistance and medically prescribed obesity treatment improves health outcomes while reducing long-term public costs.

As 2026 approaches and states reassess how SNAP is administered, Delaware’s decision not to restrict SNAP purchases, including sugar-sweetened beverages, makes this moment especially important. The question is not whether people should receive food assistance—they should—but whether public benefits can be structured to better support both access to food and access to effective obesity treatment.

Delaware has an opportunity to lead. By piloting a coordinated SNAP and Medicaid approach to obesity and carefully tracking health outcomes and costs, the state could help determine whether smarter alignment can make public assistance healthier, more effective, and more sustainable for the future.

Source